SARASOTA, Fla., Sept. 28,
2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq:
INVO) ("INVO" or the "Company"), a healthcare services fertility
company focused on expanding access to advanced treatment worldwide
with its INVOcell® medical device and the intravaginal
culture ("IVC") procedure it enables, reminds its shareholders to
vote ahead of the upcoming special meeting of shareholders (the
"Special Meeting") to be held on September
29, 2023 at 12:00 pm (Eastern
time). The Board of Directors of INVO (the "Board")
unanimously recommends that the Company's shareholders vote "FOR"
all proposals. Only shareholders of record as of the close of
business on August 21, 2023 will be
entitled to notice of, and to vote at, the Special Meeting.
"We encourage our shareholders to vote for the proposals in
order to provide the company the ability to capitalize on its
recent progress and continue its growth objectives," commented
Steve Shum, CEO of INVO.
All votes are important, regardless of the number of shares
owned. Shareholders as of Special Meeting record date, August
21, 2023, will be entitled to vote at the Special Meeting.
Shareholders are encouraged to read about the proposals in the
Company's Definitive Proxy Statement on Schedule 14A that was filed
with the Securities and Exchange Commission ("SEC")
on September 1, 2023 (the "Proxy Statement")
In addition to voting by submitting your proxy prior to the
Special Meeting, you also will be able to vote your shares
electronically during the Special Meeting. Further details
regarding the virtual meeting are included in the Proxy Statement
sent to all shareholders. At the Special Meeting, the holders
of our outstanding common stock will act on the following
matters:
- To approve an increase to the number of authorized shares of
common stock of the Company from 6,250,000 shares to 50,000,000
shares (the "Authorized Share Increase");
- To approve, for the purposes of Nasdaq Marketplace Rule
5635(d), the reduction of the exercise price for the March 2023 private placement warrants from
$12.60 per share to $2.85 per share (the "Warrant Exercise Price
Reduction"); and
- To transact such other business as may properly be brought
before the Special Meeting or any adjournment or postponement
thereof.
If you are a shareholder of record, you may vote in one of the
following ways:
- Vote over the Internet, by going
to www.proxyvote.com (have your Notice or proxy card in
hand when you access the website);
- Vote by Mail, by returning the their proxy card (signed and
dated) in the envelope provided;
- Vote by phone by calling 1-800-690-6903; or
- Vote online at the Special Meeting
at www.virtualshareholdermeeting.com/INVO2023SM.
If your shares are held in "street name," meaning that they are
held for your account by a broker or other nominee, you will
receive instructions from the holder of record that you must follow
for your shares to be voted.
The Special Meeting will be a virtual shareholder meeting,
conducted via live audio webcast, through which you can submit
questions and vote online. The Special Meeting can be accessed
by
visiting www.virtualshareholdermeeting.com/INVO2023SM and
entering your 16-digit control number (included on the Notice
Regarding the Availability of Proxy Materials mailed to you).
Whether or not you plan to attend the Special Meeting
virtually, we urge you to take the time to vote your
shares.
Additional Information
We have filed the Proxy Statement with the U.S. Securities
and Exchange Commission ("SEC") on September 1,
2023 in connection with our solicitation of proxies for the
Special Meeting. INVO BIOSCIENCE, INC. SHAREHOLDERS ARE
STRONGLY ENCOURAGED TO READ THE PROXY STATEMENT (AND ANY AMENDMENTS
AND SUPPLEMENTS THERETO) AND ACCOMPANYING PROXY CARD AS THEY
CONTAIN IMPORTANT INFORMATION. Shareholders may obtain the Proxy
Statement, any amendments or supplements to the Proxy Statement and
other documents as and when filed by us with
the SEC without charge from the SEC's website
at www.sec.gov. Shareholders can also obtain, without charge,
a copy of the Proxy Statement and other relevant filed documents
from our website at https://www.invobioscience.com/investors/.
About INVO Bioscience
We are a healthcare services fertility company dedicated to
expanding the assisted reproductive technology ("ART") marketplace
by making fertility care accessible and inclusive to people around
the world. Our commercialization strategy is focused on the opening
of dedicated "INVO Centers" offering the INVOcell® and IVC
procedure (with three centers in North
America now operational), the acquisition of US-based,
profitable in vitro fertilization ("IVF") clinics and the sale and
distribution of our technology solution into existing fertility
clinics. Our proprietary technology, INVOcell®, is a revolutionary
medical device that allows fertilization and early embryo
development to take place in vivo within the woman's body. This
treatment solution is the world's first intravaginal culture
technique for the incubation of oocytes and sperm during
fertilization and early embryo development. This technique,
designated as "IVC", provides patients a more natural, intimate,
and more affordable experience in comparison to other ART
treatments. We believe the IVC procedure can deliver comparable
results at a fraction of the cost of traditional IVF and is a
significantly more effective treatment than intrauterine
insemination ("IUI"). For more information, please
visit www.invobio.com.
Safe Harbor Statement
This release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
The Company invokes the protections of the Private Securities
Litigation Reform Act of 1995. All statements regarding our
expected future financial position, results of operations, cash
flows, financing plans, business strategies, products and services,
competitive positions, growth opportunities, plans and objectives
of management for future operations, as well as statements that
include words such as "anticipate," "if," "believe," "plan,"
"estimate," "expect," "intend," "may," "could," "should," "will,"
and other similar expressions are forward-looking statements. All
forward-looking statements involve risks, uncertainties, and
contingencies, many of which are beyond our control, which may
cause actual results, performance, or achievements to differ
materially from anticipated results, performance, or achievements.
Factors that may cause actual results to differ materially from
those in the forward-looking statements include those set forth in
our filings at www.sec.gov. We are under no obligation
to (and expressly disclaim any such obligation to) update or alter
our forward-looking statements, whether as a result of new
information, future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invo-reminds-shareholders-to-cast-their-vote-for-upcoming-special-meeting-of-shareholders-to-be-held-on-friday-september-29-2023-at-1200-pm-et-301942061.html
SOURCE INVO Bioscience, Inc.